ATEMPT试验(TBCRC 033)的局部治疗结局与毒性:一项在I期HER2阳性乳腺癌女性中比较辅助曲妥珠单抗美坦新与紫杉醇联合曲妥珠单抗的II期随机试验
ATEMPT试验(TBCRC 033)的回顾性分析评估了I期HER2阳性乳腺癌患者在接受辅助T-DM1或紫杉醇联合曲妥珠单抗期间放疗的安全性和疗效。放疗与两种方案同期给予时耐受性良好;在接受保乳手术的患者中,大分割放疗的≥2级急性皮肤毒性低于常规分割放疗。尽管随访时间短,局部复发不常见。
要点
- 放疗与T-DM1或TH同期给予时耐受性良好。
- 保乳患者中大分割放疗的≥2级急性皮肤毒性低于常规分割。
- 随访时间短,但局部复发不常见。
核心结论
- 放疗与T-DM1或TH同期给予时耐受性良好。
- 在保乳手术患者中,即使同期抗HER2治疗,大分割放疗的≥2级急性皮肤毒性更低。
- 尽管随访时间短,局部复发不常见,印证了抗HER2治疗联合放疗的疗效。
研究设计与样本
- ATEMPT试验(TBCRC 033)是一项II期随机试验,患者按3:1随机接受辅助T-DM1或TH。
- 本分析为回顾性分析,评估放疗的安全性和疗效。
- 497例患者启动了方案治疗;299例保乳患者中289例接受全乳放疗、10例接受部分乳腺放疗;8例乳房切除患者接受放疗。
主要发现
- 全乳放疗患者中,T-DM1组40.2%、TH组41.5%接受大分割(≥2.5 Gy/次)放疗。
- ≥2级皮肤毒性在T-DM1组为33.9%,TH组为23.2%(P = .11)。
- 常规分割全乳放疗患者中44.7%发生≥2级皮肤毒性,大分割组为17.9%(P < .001)。
- 放疗后5例患者发生肺炎(T-DM1组4例,1.0%;TH组1例,0.9%)。
- 3年无侵袭性疾病生存率T-DM1组为97.8%(95%CI 96.3-99.3),TH组为93.4%(95%CI 88.7-98.2);18例无侵袭性疾病生存事件中7例为孤立局部区域复发(T-DM1组2例,TH组5例)。
局限性
- 随访时间短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Human epidermal growth factor receptor 2 (HER2)-directed therapy improves local control among women with HER2-positive breast cancer. This retrospective analysis evaluates the safety and efficacy of radiation therapy (RT) among patients receiving adjuvant trastuzumab emtansine (T-DM1) or paclitaxel (T) plus trastuzumab (H) in the ATEMPT (Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab) trial; Translational Breast Cancer Research Consortium (TBCRC) 033. METHODS AND MATERIALS: Patients with stage I HER2-positive breast cancer were randomized 3:1 to receive adjuvant T-DM1 or TH after mastectomy or breast-conserving surgery (BCS). Breast RT was required after BCS and permitted after mastectomy. Patients receiving T-DM1 began RT after 12 weeks of therapy and received RT concurrently with T-DM1. Patients receiving TH began RT after paclitaxel, but concurrent with trastuzumab. RT records were retrospectively reviewed to determine details of radiation delivery and acute RT-related toxicity. RESULTS: Protocol therapy was initiated by 497 patients. Among the 299 BCS patients, 289 received whole breast RT (WBRT) and 10 partial breast. Among WBRT patients, 40.2% in the T-DM1 arm and 41.5% of TH patients received hypofractionated (≥2.5 Gy/fraction) RT. Eight mastectomy patients received RT, all conventional fractionation. Skin toxicity (grade ≥2) was seen in 33.9% of patients in the T-DM1 arm and 23.2% in the TH arm (P = .11). In conventionally fractionated WBRT patients, 44.7% had a grade ≥2 skin toxicity compared with 17.9% of patients receiving hypofractionation (P < .001). Five patients experienced pneumonitis after RT (T-DM1: n = 4, 1.0%; TH: n = 1, 0.9%). Three-year invasive disease-free survival was 97.8% for T-DM1 (95% confidence interval, 96.3-99.3) and 93.4% for TH (95% confidence interval, 88.7-98.2). Among the 18 invasive disease-free survival events, 7 were isolated locoregional recurrences (2, T-DM1; 5, TH). CONCLUSIONS: RT was well-tolerated when given concurrently with either T-DM1 or TH. Among BCS patients, hypofractionation resulted in lower grade ≥2 acute skin toxicity even with concurrent anti-HER2 therapy. Although follow-up was short, local recurrences were uncommon, attesting to the efficacy of HER2-directed therapy combined with RT.
引用
- Bellon JR, Tayob N, Yang DD, et al. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 34990776. doi:10.1016/j.ijrobp.2021.12.173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。